EXSCIENTIA PLC (EXAI)

Company Profile

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 481 full-time employees. The company went IPO on 2021-10-01. The company is focused on discovering, designing and developing the possible drugs. The company has developed the functional precision oncology platform to guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Its internal pipeline is focused on leveraging its precision medicine platform in oncology, while its partnered pipeline broadens its approach to other therapeutic areas. Its patient-first AI platform includes Precision Target, Precision Design, Precision Experiment, Precision Medicine, Presentations and Publications. Its Precision Target combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. Its advanced biophysical and x-ray techniques provide the ideal experimental underpinnings for AI-design.

Company Info

EXSCIENTIA PLC

The Schrodinger Building, Oxford Science Park

Oxford OXFORDSHIRE

P: 441865818941

Employees: 481

Website: https://www.exscientia.ai/